A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2002

Study Completion Date

December 31, 2003

Conditions
Crohn's Disease
Interventions
DRUG

CC-5013

Trial Locations (20)

20010

Washington Hospital Center Physicians Office Building, Washington D.C.

27612

Wake Research Associates, Raleigh

52621

Department of Gastroenterology and Hepatology, Tel Litwinsky

75010

Hopital Saint Louis, Paris

85712

Advanced Clinical Therapeutics, Tucson

91120

Department of Medicine A, Liver & Gastroenterology Units, Jerusalem

92801

Advanced Clinical Research Institute, Anaheim

62794-9248

Springfield Clinic, Springfield

Unknown

Rambam Hospital, Haifa

Nottingham

DA2 8DA

Department of Gastroenterology, Dartford

BS2 8HW

Department of Gastroenterology, Bristol

CB2 2QQ

Addenbrookes Hospital, Cambridge

CF 14 4XW

Department of Medicine, Cardiff

NW3 2QG

Department of Gastroenterology, London

W12 0HS

Department of Gastroenterology, London

W1N 8AA

Department of Gastroenterology, London

M13 9WL

Department of Gastroenterology, Manchester

HA 1 3UI

St. Mark's Hospital, Middlesex

NE1 4LP

Department of Gastroentroerology, Newcastle

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY